Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

Published:2016-02 Issue: Volume: Page:773
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Kaseb Ahmed,Morris Jeffrey,Iwasaki Michiko,Al-Shamsi Humaid,Raghav Kanwal,Girard Lauren,Cheung Sheree,Nguyen Van,Elsayes Khaled,Xiao Lianchun,Abdel-Wahab Reham,Shalaby Ahmed,Hassan Manal,Hassabo Hesham,Wolff Robert,Yao James

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review;TRANSL CANCER RES;2024

2. Insights in Molecular Therapies for Hepatocellular Carcinoma;Cancers;2024-05-10

3. New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow;International Journal of Molecular Sciences;2024-01-25

4. Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2023-11

5. Inactivation of EGFR/ERK/NF‐κB signalling associates with radiosensitizing effect of 18β‐glycyrrhetinic acid on progression of hepatocellular carcinoma;Journal of Cellular and Molecular Medicine;2023-05-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP